Xenetic Biosciences is honing in on the revolutionary XCART technology, a personalized chimeric antigen receptor T cell (CAR T) platform designed to specifically target patient-specific tumor neoantigens. The biopharmaceutical company is also committed to advancing the production of biologic drugs and therapeutics and developing cell-based therapeutics targeting the B-cell receptor in individuals suffering from B-cell lymphomas. Moreover, the company is leveraging its proprietary drug delivery platform, PolyXen, through collaborations with esteemed biotechnology and pharmaceutical companies such as Takeda Pharmaceutical, Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc., headquartered in Framingham, Massachusetts, remains at the forefront of innovative biopharmaceutical research and development.
Xenetic Biosciences, Inc.'s ticker is XBIO
The company's shares trade on the NASDAQ stock exchange
They are based in Framingham, Massachusetts
There are 1-10 employees working at Xenetic Biosciences, Inc.
It is https://www.xeneticbio.com/
Xenetic Biosciences, Inc. is in the Healthcare sector
Xenetic Biosciences, Inc. is in the Biotechnology industry
The following five companies are Xenetic Biosciences, Inc.'s industry peers: